News Releases

scPharmaceuticals Inc. Provides Regulatory Update on FUROSCIX®
Type C Meeting confirmed that FDA does not believe additional clinical safety, efficacy, or pharmacology studies will be required to support NDA resubmission and review FDA confirmed that the resubmission would be under the current NDA Company accelerates timeline and now expects resubmission of[…]
scPharmaceuticals Inc. to Present at Upcoming Investor Conferences
BURLINGTON, Mass. , May 30, 2019 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today[…]
scPharmaceuticals Inc. Reports First Quarter 2019 Financial Results and Provides Business Update
Type C Meeting to solidify re-filing plans for FUROSCIX® scheduled with the U.S. Food and Drug Administration ( FDA ) for June 2019 Resubmission of FURSOCIX New Drug Application (NDA) with the FDA in 2020 Balance sheet remains strong with over $83 million in cash BURLINGTON, Mass.[…]
scPharmaceuticals Inc. Reports Fourth Quarter and Year Ended 2018 Financial Results and Provides Business Update
Signed development agreement with West Pharmaceutical Services for next-generation FUROSCIX ® On-Body Infusor Resubmission of FURSOCIX with the U.S. Food and Drug Administration ( FDA ) by year-end 2020 Balance sheet remains strong with over $89 million in cash BURLINGTON, Mass.[…]
scPharmaceuticals Inc. to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference
BURLINGTON, Mass. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs, today[…]
scPharmaceuticals Inc. Announces Development Agreement with West Pharmaceutical Services for Next-Generation FUROSCIX® On-Body Infusor
Advancing FUROSCIX ® with the SmartDose ® Drug Delivery System Forecast 2018 year-end cash of $82 - $87 million and 2019 expenditures of  $8 - $10 million per quarter BURLINGTON, Mass. , Jan. 29, 2019 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on[…]